NCT02762084View on ClinicalTrials.gov

Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

June 6, 2016

Primary Completion Date

April 24, 2017

Study Completion Date

April 24, 2017

Conditions

Basal Cell Nevus Syndrome

Interventions

DRUG

Patidegib

DRUG

Vehicle gel

Trial Locations (2)

Unknown

Royal London Hospital, London

Manchester Royal Infirmary, Manchester

Sponsors

Lead Sponsor

PellePharm, Inc.

All Listed Sponsors

lead

PellePharm, Inc.

INDUSTRY